Clinical Trial Update: Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation and expansion study of CPO107 in patients with advanced CD20-positive non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CPO107

Snippet

Sponsor: Conjupro Biotherapeutics, Inc. | Conditions: CD20 Positive Non Hodgkin Lymphoma | Phase 1 | Status: TERMINATED